Subscribe to our Newsletters !!


    Zydus Cadila gets provisional endorsement from USFDA for Droxidopa Capsules, 100 mg, 200 mg, and 300 mg

    Zydus Cadila has gotten provisional endorsement from the USFDA to advertise Droxidopa Capsules, (US RLD: Northera®) in the qualities of 100 mg, 200 mg, and 300 mg. Droxidopa is utilized to treat indications of low pulse when standing, brought about by a specific ailment (neurogenic orthostatic hypotension-nOH). This drug can diminish indications of low circulatory

    India’s Zydus Cadila to make Gilead’s potential COVID-19 medication remdesivir

    Indian drugmaker Zydus Cadila said on Friday it marked a non-selective permitting agreement with Gilead Sciences Inc to make and market antiviral medication remdesivir, the main treatment to show improvement in COVID-19 preliminaries. Zydus, recorded as Cadila Healthcare, joins other Indian pharmaceutical organizations Cipla Ltd, Jubilant Sciences Ltd and secretly held Hetero Labs Ltd in

    Zydus Cadila gets final approval from USFDA to Advertise generic tension headache Pills

    Medication firm Zydus Cadila on Saturday said it has received final approval from the US health regulator to market generic Butalbital, Acetaminophen and Caffeine combination pills to cure symptoms of tension headaches. The company has obtained final approval from that the United States Food and Drug Administration (USFDA) to market Butalbital, Acetaminophen and Caffeine tablets

    Zydus Cadila dispatches COVID-19 medication Remdesivir in India

    Drug firm Zydus Cadila on August 13 stated it has established Remdesivir under the brand name Remdac, used to treat patients experiencing severe signs of COVID-19, in the Indian market. Priced at Rs 2,800 per 100 mg vial, Remdac is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing. The

    Zydus Cadila gets USFDA gesture for muscle relaxant infusion

    Zydus Cadila has obtained final acceptance by the US Food and Drug Administration (USFDA) to advertise Cisatracurium Besylate Injection USP at the potency of 20 milligrams (base)/10 mL (two mg/mL) multiple-dose vial, Cadila Healthcare stated in a regulatory filing on Wednesday. The drug will be produced in Liva plant of Cadila Healthcare Ltd.. Zydus Cadila

    Zydus Cadila gets USFDA gesture for numerous sclerosis treatment drug

    Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Dimethyl Fumarate delayed release capsules, (Tecfidera) in the strengths of 120 mg and 240 mg, Zydus Cadila, part of Cadila Healthcare group, said in a regulatory filing. Zydus Cadila said in its approval, the USFDA noted that Zydus